Viral protease inhibitors.
Identifieur interne : 001D97 ( Ncbi/Checkpoint ); précédent : 001D96; suivant : 001D98Viral protease inhibitors.
Auteurs : Jeffrey Anderson [États-Unis] ; Celia Schiffer ; Sook-Kyung Lee ; Ronald SwanstromSource :
- Handbook of experimental pharmacology [ 0171-2004 ] ; 2009.
Descripteurs français
- KwdFr :
- Animaux, Antiviraux (pharmacologie), Association de médicaments, Cysteine endopeptidases, Cytomegalovirus (), Cytomegalovirus (enzymologie), Hepacivirus (), Hepacivirus (enzymologie), Humains, Inhibiteurs de protéase du VIH (pharmacologie), Inhibiteurs de protéases (pharmacologie), Modèles moléculaires, Peptide hydrolases (), Protéines virales (antagonistes et inhibiteurs), Protéines virales non structurales (antagonistes et inhibiteurs), Résistance virale aux médicaments, Virus (), Virus (enzymologie), Virus du SRAS (), Virus du SRAS (enzymologie).
- MESH :
- antagonistes et inhibiteurs : Protéines virales, Protéines virales non structurales.
- enzymologie : Cytomegalovirus, Hepacivirus, Virus, Virus du SRAS.
- pharmacologie : Antiviraux, Inhibiteurs de protéase du VIH, Inhibiteurs de protéases.
- Animaux, Association de médicaments, Cysteine endopeptidases, Cytomegalovirus, Hepacivirus, Humains, Modèles moléculaires, Peptide hydrolases, Résistance virale aux médicaments, Virus, Virus du SRAS.
English descriptors
- KwdEn :
- Animals, Antiviral Agents (pharmacology), Cysteine Endopeptidases, Cytomegalovirus (drug effects), Cytomegalovirus (enzymology), Drug Resistance, Viral, Drug Therapy, Combination, HIV Protease Inhibitors (pharmacology), Hepacivirus (drug effects), Hepacivirus (enzymology), Humans, Models, Molecular, Peptide Hydrolases (chemistry), Protease Inhibitors (pharmacology), SARS Virus (drug effects), SARS Virus (enzymology), Viral Nonstructural Proteins (antagonists & inhibitors), Viral Proteins (antagonists & inhibitors), Viruses (drug effects), Viruses (enzymology).
- MESH :
- chemical , antagonists & inhibitors : Viral Nonstructural Proteins, Viral Proteins.
- chemical , chemistry : Peptide Hydrolases.
- chemical , pharmacology : Antiviral Agents, HIV Protease Inhibitors, Protease Inhibitors.
- drug effects : Cytomegalovirus, Hepacivirus, SARS Virus, Viruses.
- enzymology : Cytomegalovirus, Hepacivirus, SARS Virus, Viruses.
- Animals, Cysteine Endopeptidases, Drug Resistance, Viral, Drug Therapy, Combination, Humans, Models, Molecular.
Abstract
This review provides an overview of the development of viral protease inhibitors as antiviral drugs. We concentrate on HIV-1 protease inhibitors, as these have made the most significant advances in the recent past. Thus, we discuss the biochemistry of HIV-1 protease, inhibitor development, clinical use of inhibitors, and evolution of resistance. Since many different viruses encode essential proteases, it is possible to envision the development of a potent protease inhibitor for other viruses if the processing site sequence and the catalytic mechanism are known. At this time, interest in developing inhibitors is limited to viruses that cause chronic disease, viruses that have the potential to cause large-scale epidemics, or viruses that are sufficiently ubiquitous that treating an acute infection would be beneficial even if the infection was ultimately self-limiting. Protease inhibitor development is most advanced for hepatitis C virus (HCV), and we also provide a review of HCV NS3/4A serine protease inhibitor development, including combination therapy and resistance. Finally, we discuss other viral proteases as potential drug targets, including those from Dengue virus, cytomegalovirus, rhinovirus, and coronavirus.
DOI: 10.1007/978-3-540-79086-0_4
PubMed: 19048198
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001A22
- to stream PubMed, to step Curation: 001A22
- to stream PubMed, to step Checkpoint: 001740
- to stream Ncbi, to step Merge: 001D97
- to stream Ncbi, to step Curation: 001D97
Links to Exploration step
pubmed:19048198Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Viral protease inhibitors.</title><author><name sortKey="Anderson, Jeffrey" sort="Anderson, Jeffrey" uniqKey="Anderson J" first="Jeffrey" last="Anderson">Jeffrey Anderson</name><affiliation wicri:level="4"><nlm:affiliation>Division of Infectious Diseases, Department of Internal Medicine, University of Massachusetts, Worcester, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Infectious Diseases, Department of Internal Medicine, University of Massachusetts, Worcester, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region><settlement type="city">Amherst (Massachusetts)</settlement></placeName><orgName type="university">Université du Massachusetts</orgName></affiliation></author><author><name sortKey="Schiffer, Celia" sort="Schiffer, Celia" uniqKey="Schiffer C" first="Celia" last="Schiffer">Celia Schiffer</name></author><author><name sortKey="Lee, Sook Kyung" sort="Lee, Sook Kyung" uniqKey="Lee S" first="Sook-Kyung" last="Lee">Sook-Kyung Lee</name></author><author><name sortKey="Swanstrom, Ronald" sort="Swanstrom, Ronald" uniqKey="Swanstrom R" first="Ronald" last="Swanstrom">Ronald Swanstrom</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:19048198</idno><idno type="pmid">19048198</idno><idno type="doi">10.1007/978-3-540-79086-0_4</idno><idno type="wicri:Area/PubMed/Corpus">001A22</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001A22</idno><idno type="wicri:Area/PubMed/Curation">001A22</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001A22</idno><idno type="wicri:Area/PubMed/Checkpoint">001740</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001740</idno><idno type="wicri:Area/Ncbi/Merge">001D97</idno><idno type="wicri:Area/Ncbi/Curation">001D97</idno><idno type="wicri:Area/Ncbi/Checkpoint">001D97</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Viral protease inhibitors.</title><author><name sortKey="Anderson, Jeffrey" sort="Anderson, Jeffrey" uniqKey="Anderson J" first="Jeffrey" last="Anderson">Jeffrey Anderson</name><affiliation wicri:level="4"><nlm:affiliation>Division of Infectious Diseases, Department of Internal Medicine, University of Massachusetts, Worcester, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Infectious Diseases, Department of Internal Medicine, University of Massachusetts, Worcester, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region><settlement type="city">Amherst (Massachusetts)</settlement></placeName><orgName type="university">Université du Massachusetts</orgName></affiliation></author><author><name sortKey="Schiffer, Celia" sort="Schiffer, Celia" uniqKey="Schiffer C" first="Celia" last="Schiffer">Celia Schiffer</name></author><author><name sortKey="Lee, Sook Kyung" sort="Lee, Sook Kyung" uniqKey="Lee S" first="Sook-Kyung" last="Lee">Sook-Kyung Lee</name></author><author><name sortKey="Swanstrom, Ronald" sort="Swanstrom, Ronald" uniqKey="Swanstrom R" first="Ronald" last="Swanstrom">Ronald Swanstrom</name></author></analytic><series><title level="j">Handbook of experimental pharmacology</title><idno type="ISSN">0171-2004</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiviral Agents (pharmacology)</term><term>Cysteine Endopeptidases</term><term>Cytomegalovirus (drug effects)</term><term>Cytomegalovirus (enzymology)</term><term>Drug Resistance, Viral</term><term>Drug Therapy, Combination</term><term>HIV Protease Inhibitors (pharmacology)</term><term>Hepacivirus (drug effects)</term><term>Hepacivirus (enzymology)</term><term>Humans</term><term>Models, Molecular</term><term>Peptide Hydrolases (chemistry)</term><term>Protease Inhibitors (pharmacology)</term><term>SARS Virus (drug effects)</term><term>SARS Virus (enzymology)</term><term>Viral Nonstructural Proteins (antagonists & inhibitors)</term><term>Viral Proteins (antagonists & inhibitors)</term><term>Viruses (drug effects)</term><term>Viruses (enzymology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Antiviraux (pharmacologie)</term><term>Association de médicaments</term><term>Cysteine endopeptidases</term><term>Cytomegalovirus ()</term><term>Cytomegalovirus (enzymologie)</term><term>Hepacivirus ()</term><term>Hepacivirus (enzymologie)</term><term>Humains</term><term>Inhibiteurs de protéase du VIH (pharmacologie)</term><term>Inhibiteurs de protéases (pharmacologie)</term><term>Modèles moléculaires</term><term>Peptide hydrolases ()</term><term>Protéines virales (antagonistes et inhibiteurs)</term><term>Protéines virales non structurales (antagonistes et inhibiteurs)</term><term>Résistance virale aux médicaments</term><term>Virus ()</term><term>Virus (enzymologie)</term><term>Virus du SRAS ()</term><term>Virus du SRAS (enzymologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Viral Nonstructural Proteins</term><term>Viral Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Peptide Hydrolases</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term><term>HIV Protease Inhibitors</term><term>Protease Inhibitors</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Protéines virales</term><term>Protéines virales non structurales</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cytomegalovirus</term><term>Hepacivirus</term><term>SARS Virus</term><term>Viruses</term></keywords><keywords scheme="MESH" qualifier="enzymologie" xml:lang="fr"><term>Cytomegalovirus</term><term>Hepacivirus</term><term>Virus</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>Cytomegalovirus</term><term>Hepacivirus</term><term>SARS Virus</term><term>Viruses</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term><term>Inhibiteurs de protéase du VIH</term><term>Inhibiteurs de protéases</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cysteine Endopeptidases</term><term>Drug Resistance, Viral</term><term>Drug Therapy, Combination</term><term>Humans</term><term>Models, Molecular</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Association de médicaments</term><term>Cysteine endopeptidases</term><term>Cytomegalovirus</term><term>Hepacivirus</term><term>Humains</term><term>Modèles moléculaires</term><term>Peptide hydrolases</term><term>Résistance virale aux médicaments</term><term>Virus</term><term>Virus du SRAS</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This review provides an overview of the development of viral protease inhibitors as antiviral drugs. We concentrate on HIV-1 protease inhibitors, as these have made the most significant advances in the recent past. Thus, we discuss the biochemistry of HIV-1 protease, inhibitor development, clinical use of inhibitors, and evolution of resistance. Since many different viruses encode essential proteases, it is possible to envision the development of a potent protease inhibitor for other viruses if the processing site sequence and the catalytic mechanism are known. At this time, interest in developing inhibitors is limited to viruses that cause chronic disease, viruses that have the potential to cause large-scale epidemics, or viruses that are sufficiently ubiquitous that treating an acute infection would be beneficial even if the infection was ultimately self-limiting. Protease inhibitor development is most advanced for hepatitis C virus (HCV), and we also provide a review of HCV NS3/4A serine protease inhibitor development, including combination therapy and resistance. Finally, we discuss other viral proteases as potential drug targets, including those from Dengue virus, cytomegalovirus, rhinovirus, and coronavirus.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Massachusetts</li></region><settlement><li>Amherst (Massachusetts)</li></settlement><orgName><li>Université du Massachusetts</li></orgName></list><tree><noCountry><name sortKey="Lee, Sook Kyung" sort="Lee, Sook Kyung" uniqKey="Lee S" first="Sook-Kyung" last="Lee">Sook-Kyung Lee</name><name sortKey="Schiffer, Celia" sort="Schiffer, Celia" uniqKey="Schiffer C" first="Celia" last="Schiffer">Celia Schiffer</name><name sortKey="Swanstrom, Ronald" sort="Swanstrom, Ronald" uniqKey="Swanstrom R" first="Ronald" last="Swanstrom">Ronald Swanstrom</name></noCountry><country name="États-Unis"><region name="Massachusetts"><name sortKey="Anderson, Jeffrey" sort="Anderson, Jeffrey" uniqKey="Anderson J" first="Jeffrey" last="Anderson">Jeffrey Anderson</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D97 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 001D97 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Ncbi
|étape= Checkpoint
|type= RBID
|clé= pubmed:19048198
|texte= Viral protease inhibitors.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:19048198" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |